MX2024005746A - Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos. - Google Patents

Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.

Info

Publication number
MX2024005746A
MX2024005746A MX2024005746A MX2024005746A MX2024005746A MX 2024005746 A MX2024005746 A MX 2024005746A MX 2024005746 A MX2024005746 A MX 2024005746A MX 2024005746 A MX2024005746 A MX 2024005746A MX 2024005746 A MX2024005746 A MX 2024005746A
Authority
MX
Mexico
Prior art keywords
magea1
immunogenic peptides
binding proteins
proteins recognizing
recognizing
Prior art date
Application number
MX2024005746A
Other languages
English (en)
Spanish (es)
Inventor
Kai Wucherpfennig
Gavin Macbeath
Yifan Wang
Jenny Tadros
Nancy Nabilsi
Jonathan Schoenfeld
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of MX2024005746A publication Critical patent/MX2024005746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
MX2024005746A 2021-11-10 2022-11-10 Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos. MX2024005746A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163277924P 2021-11-10 2021-11-10
US202263317337P 2022-03-07 2022-03-07
US202263342415P 2022-05-16 2022-05-16
PCT/US2022/049556 WO2023086480A2 (en) 2021-11-10 2022-11-10 Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof

Publications (1)

Publication Number Publication Date
MX2024005746A true MX2024005746A (es) 2024-07-19

Family

ID=86336428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005746A MX2024005746A (es) 2021-11-10 2022-11-10 Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.

Country Status (11)

Country Link
US (1) US20230270832A1 (https=)
EP (1) EP4430067A2 (https=)
JP (1) JP2024546018A (https=)
KR (1) KR20240112285A (https=)
AU (2) AU2022268347C1 (https=)
CA (1) CA3237903A1 (https=)
CO (1) CO2024007212A2 (https=)
IL (1) IL312744A (https=)
MX (1) MX2024005746A (https=)
TW (1) TW202340224A (https=)
WO (1) WO2023086480A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116716327B (zh) * 2023-08-04 2023-10-20 科士华(南京)生物技术有限公司 一种构建tcr载体的方法
TW202523702A (zh) * 2023-10-27 2025-06-16 美商帝斯肯醫療公司 Magea1免疫原性肽、識別magea1免疫原性肽之結合蛋白及其用途
TWI871128B (zh) * 2023-12-08 2025-01-21 陳乃銘 可準確提供循環腫瘤細胞（ｃｔｃ）所需藥物種類之方法
WO2025217037A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of binding proteins for treatment of solid tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
WO2005115447A2 (en) * 2004-05-25 2005-12-08 The Trustees Of The University Of Pennsylvania Human anti-cancer immunotherapy
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AU2017252192C1 (en) * 2016-04-19 2023-06-08 Imcyse Sa Novel immunogenic CD1d binding peptides
CN113795586B (zh) * 2019-03-25 2026-03-27 大学健康网络 T细胞受体及其使用方法
WO2021119545A1 (en) * 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
US11464842B1 (en) * 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Also Published As

Publication number Publication date
CA3237903A1 (en) 2023-05-19
CO2024007212A2 (es) 2024-09-09
US20230270832A1 (en) 2023-08-31
AU2022268347C1 (en) 2024-04-18
EP4430067A2 (en) 2024-09-18
JP2024546018A (ja) 2024-12-17
AU2022268347A1 (en) 2023-05-25
WO2023086480A2 (en) 2023-05-19
TW202340224A (zh) 2023-10-16
WO2023086480A3 (en) 2023-06-29
AU2022268347B2 (en) 2024-01-18
KR20240112285A (ko) 2024-07-18
AU2024200495A1 (en) 2024-02-15
IL312744A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
MX2024005746A (es) Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.
MX2023012141A (es) Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos.
AU2021311470A1 (en) Binding proteins recognizing SARS-CoV-2 antigens and uses thereof
MX2023012111A (es) Proteinas de union que reconocen el antigeno ha-2 y usos de estas.
WO2018187356A3 (en) Protein antigens and uses thereof
WO2020193688A3 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
WO2022099100A3 (en) Binding proteins recognizing ha-1 antigen and uses thereof
WO2020142659A3 (en) Multi-specific protein molecules and uses thereof
PL1731605T3 (pl) Nowotworowe peptydy antygenowe pochodzące z WT1
EP4527466A3 (en) Anti-dll3 chimeric antigen receptors and uses thereof
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2024005743A (es) Proteinas de union que reconocen al antigeno hpv16 e7 y usos de las mismas.
EA202190136A1 (ru) Способ очистки антигена
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
WO2020227228A3 (en) Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
EP1530637A4 (en) SUBTILISIN CARLSBERG PROTEINS WITH REDUCED IMMUNOGENICITY
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
WO2023009529A3 (en) Novel polypeptides and uses thereof
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
WO2020079448A9 (en) Novel cancer antigens and methods
WO2019210055A3 (en) Heat shock protein-binding peptide compositions and methods of use thereof
WO2024077134A8 (en) Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
IL325709A (en) Anti-a-beta protein antibodies, methods and uses thereof
MX2025004044A (es) Peptidos inmunogenicos magea1, proteinas de union que reconocen a los peptidos inmunogenicos magea1 y usos de los mismos